Cited by 312Genetic Neurodegenerative DiseasesCoenzyme Q10 studies and effectsNeurological diseases and metabolism

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

The Huntington Study Group·2001·Neurology

Open this paper in CoChat — free account

Abstract

OBJECTIVES: To determine whether chronic treatment with coenzyme Q10 or remacemide hydrochloride slows the functional decline of early Huntington's disease (HD). METHODS: The authors conducted a multicenter, parallel group, double-blind, 2 x 2 factorial, randomized clinical trial. Research participants with early HD (n = 347) were randomized to receive coenzyme Q10 300 mg twice daily, remacemide hydrochloride 200 mg three times daily, both, or neither treatment, and were evaluated every 4 to 5 months for a total of 30 months on assigned treatment. The prespecified primary measure of efficacy was the change in total functional capacity (TFC) between baseline and 30 months. Safety measures included the frequency of clinical adverse events. RESULTS: Neither intervention significantly altered the decline in TFC. Patients treated with coenzyme Q10 showed a trend toward slowing in TFC decline (13%) over 30 months (2.40- versus 2.74-point decline, p = 0.15), as well as beneficial trends in some secondary measures. There was increased frequency of nausea, vomiting, and dizziness with remacemide and increased frequency of stomach upset with coenzyme Q10. CONCLUSIONS: Neither remacemide nor coenzyme Q10, at the dosages studied, produced significant slowing in functional decline in early HD.

Integrity signals

Registry

Crossref · 10.1212/wnl.57.3.397

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Unified Huntington's disease rating scale: Reliability and consistency
Kremer, H. P. H. (1996) · Movement Disorders · doi:10.1002/mds.870110204 · Cited by 2,155
The hopkins verbal learning test: Development of a new memory test with six equivalent forms
Brandt, J. (1991) · Clinical Neuropsychologist · doi:10.1080/13854049108403297 · Cited by 1,317
Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
Huntington disease: Clinical care and evaluation
Shoulson, I., & Fahn, S. (1979) · Neurology · doi:10.1212/wnl.29.1.1 · Cited by 746
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
Rate of functional decline in Huntington’s disease
Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology · doi:10.1212/wnl.54.2.452 · Cited by 362
Self-citation
Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons
Ginsberg, S. D., Hemby, S. E., Lee, V. M. ‐., Eberwine, J. H., & Trojanowski, J. Q. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200007)48:1 · Cited by 315
Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals
Penney, J. B., Young, A. B., Shoulson, I., Starosta‐Rubinstein, S., Snodgrass, S. R., Sanchez‐Ramos, J., Ramos‐Arroyo, M. A., Gomez, F., Penchaszadeh, G. K., Alvir, J., et al. (1990) · Movement Disorders · doi:10.1002/mds.870050202 · Cited by 218
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
Hirsch, É. C., Hunot, S., Faucheux, B. A., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W. G., Tatton, N. A., & Olanow, W. C. (1999) · Movement Disorders · doi:10.1002/1531-8257(199903)14:2 · Cited by 152

Show all 19 references

Research works printed but not linked: 1

Reitan RM Wolfson D. The Halstead–Reitan Neuropsychological Test Battery. Tuscon: Neuropsychology Press 1958.

Sorted by citations

Huntington's disease
Walker, F. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60111-1 · Cited by 2,691
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,816
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target
Barber, S. C., & Shaw, P. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.018 · Cited by 647
Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease
Mahoney‐Sanchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 572
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities
Tabrizi, S. J., Flower, M. D., Ross, C. A., & Wild, E. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0389-4 · Cited by 568
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic StrategiesPreprint
Jiménez-Sánchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 534
Mitochondrial diseases
Schapira, A. H. V. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61305-6 · Cited by 514
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391
Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study
Bachoud‐Lévi, A., Gaura-Schmidt, V., Brugières, P., Lefaucheur, J., Boissé, M., Maison, P., Baudic, S., Ribeiro, M. J., Bourdet, C., Rémy, P., et al. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70381-7 · Cited by 357
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment
Beal, M. F. (2004) · Journal of Bioenergetics and Biomembranes · doi:10.1023/b:jobb.0000041772.74810.92 · Cited by 277
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 255
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice
Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Signore, S. J. D., Guélin, E., Ryu, H., Hersch, S. M., & Ferrante, R. J. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20680 · Cited by 255
Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations
Bhagavan, H. N., & Chopra, R. K. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.003 · Cited by 243
The Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges
Kamat, C. D., Gadal, S., Mhatre, M., Williamson, K. S., Pye, Q. N., & Hensley, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15314 · Cited by 238
Oxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly
Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236
Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements.
Nicolson, G. L. (2014) · PubMed Central · Cited by 235
Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases
Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., & Beal, M. F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06074.x · Cited by 237
Huntington's Disease: Can Mice Lead the Way to Treatment?
Crook, Z. R., & Housman, D. E. (2011) · Neuron · doi:10.1016/j.neuron.2010.12.035 · Cited by 236
Metformin therapy in a transgenic mouse model of Huntington's disease
Ma, T. C., Buescher, J. L., Oatis, B., Funk, J. A., Nash, A. J., Carrier, R. L., & Hoyt, K. R. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.10.039 · Cited by 224
Experimental therapeutics in transgenic mouse models of Huntington's disease
Beal, M. F., & Ferrante, R. J. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1386 · Cited by 227
Energy deficit in Huntington disease: why it matters
Mochel, F., & Haller, R. G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45691 · Cited by 220
The Spinocerebellar Ataxias
Paulson, H. L. (2009) · Journal of Neuro-Ophthalmology · doi:10.1097/wno0b013e3181b416de · Cited by 220
The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies
Li, J. Y., Popović, N., & Brundin, P. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.447 · Cited by 221
The molecular genetics of Huntington disease — a history
Bates, G. P. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1686 · Cited by 201
Dopamine and Glutamate in Huntington's Disease: A Balancing Act
André, V. M., Cepeda, C., & Levine, M. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00134.x · Cited by 194
Safety assessment of coenzyme Q 10 (CoQ 10 )
Hidaka, T., Fujii, K., Funahashi, I., Fukutomi, N., & Hosoe, K. (2008) · BioFactors · doi:10.1002/biof.5520320124 · Cited by 187
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease
Carsten Saft, C., Zange, J., Andrich, J., Müller, K., Lindenberg, K. S., Landwehrmeyer, G. B., Vorgerd, M., Kraus, P. H., Przuntek, H., & Schöls, L. J. (2005) · Movement Disorders · doi:10.1002/mds.20373 · Cited by 184
Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study
Kipps, C. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.047993 · Cited by 181
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Riluzole in Huntington's disease: a 3‐year, randomized controlled study
Landwehrmeyer, G. B., Dubois, B., de Yébenes, J. G., Kremer, B. P. H., Gaus, W., Kraus, P. H., Przuntek, H., Dib, M., Doble, A., Fischer, W., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21181 · Cited by 176
Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators
Frank, S. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-62 · Cited by 174
Minocycline and doxycycline are not beneficial in a model of Huntington's disease
Smith, D. L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi‐Noori, S., Lowden, P. A. S., Bates, G. P., & Hockly, E. (2003) · Annals of Neurology · doi:10.1002/ana.10614 · Cited by 173
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease
Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 175
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial
de Yébenes, J. G., Landwehrmeyer, G. B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R. A., Carsten Saft, C., Magnet, M. K., Sword, A., Rembratt, Å., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70233-2 · Cited by 171
Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease
Zeron, M. M., Fernandes, H. B., Krebs, C., Shehadeh, J., Wellington, C. L., Leavitt, B. R., Baimbridge, K. G., Hayden, M. R., & Raymond, L. A. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.11.014 · Cited by 170
Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants
Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169
Therapeutic approaches to Huntington disease: from the bench to the clinic
Caron, N. S., Dorsey, E. R., & Hayden, M. R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.133 · Cited by 168
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research
Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613021 · Cited by 174
Therapeutic effects of coenzyme Q 10 (CoQ 10 ) and reduced CoQ 10 in the MPTP model of Parkinsonism
Cléren, C., Yang, L., Lorenzo, B. J., Calingasan, N. Y., Schomer, A. C., Sireci, A. N., Wille, E. J., & Beal, M. F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05097.x · Cited by 158
Motor, cognitive, and functional declines contribute to a single progressive factor in early HD
Schobel, S., Palermo, G., Auinger, P., Long, J. D., Ma, S., Khwaja, O., Trundell, D., Cudkowicz, M., Hersch, S. M., Sampaio, C., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004743 · Cited by 157
The current clinical management of Huntington's disease
Phillips, W., Shannon, K. M., & Barker, R. A. (2008) · Movement Disorders · doi:10.1002/mds.21971 · Cited by 158
Alterations in synaptic function and plasticity in Huntington disease
Smith-Dijak, A., Sepers, M. D., & Raymond, L. A. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14723 · Cited by 158
Therapeutics development for triplet repeat expansion diseases
Prospero, N. A. D., & Fischbeck, K. H. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1690 · Cited by 149
Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model
Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151
Rodent genetic models of Huntington disease
Heng, M. Y., Detloff, P. J., & Albin, R. L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.06.005 · Cited by 152
The Clinical and Genetic Features of Huntington Disease
Sturrock, A., & Leavitt, B. R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383573 · Cited by 144
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry, A. J., McDermott, M., Kieburtz, K. D., de Blieck, E. A., Beal, F. M., Marder, K. S., Ross, C. A., Shoulson, I., Gilbert, P. R., Mallonee, W. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003478 · Cited by 139
Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases
Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139
Therapeutic use of coenzyme Q 10 and coenzyme Q 10 -related compounds and formulations
Villalba, J. M., Parrado‐Fernández, C., González, M. S., & Alcain, F. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727495 · Cited by 139
Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease
Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice
Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127
The uptake and distribution of coenzyme Q(10)
Miles, M. V. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.02.012 · Cited by 126
Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease
Shehadeh, J., Fernandes, H. B., Mullins, M. Z., Graham, R. K., Leavitt, B. R., Hayden, M. R., & Raymond, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.001 · Cited by 120
Symptomatic Treatment of Huntington Disease
Adam, O. R., & Jankovic, J. J. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.008 · Cited by 119
Huntingtin in health and disease
Young, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17742 · Cited by 118
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice
Stack, E. C., Smith, K. M., Ryu, H., Cormier, K., Chen, M., Hagerty, S. W., Del Signore, S. J., Cudkowicz, M. E., Friedlander, R. M., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2005.11.002 · Cited by 114
Risk assessment for coenzyme Q10 (Ubiquinone)
Hathcock, J. N., & Shao, A. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2006.05.006 · Cited by 114
Measurement and Analysis
Nelson, L. M., Tanner, C. M., Eeden, S. K. V. D., & McGuire, V. M. (2004) · Neuroepidemiology · doi:10.1093/acprof:oso/9780195133790.003.03 · Cited by 111
Chorea and related disorders
Bhidayasiri, R., & Truong, D. D. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.019356 · Cited by 110
Environmental factors as modulators of neurodegeneration: Insights from gene–environment interactions in Huntington's disease
Mo, C., Hannan, A. J., & Renoir, T. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.03.003 · Cited by 108
Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice
Signore, S. J. D., Amante, D. J., Kim, J.-H., Stack, E. C., Goodrich, S., Cormier, K., Smith, K., Cudkowicz, M., & Ferrante, R. J. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802226148 · Cited by 105
Huntington Disease and the Huntingtin Protein
Zheng, Z., & Diamond, M. I. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00010-2 · Cited by 118
Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial
Ikematsu, H., Nakamura, K., Harashima, S., Fujii, K., & Fukutomi, N. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2005.12.002 · Cited by 104
Mouse models of Huntington disease: variations on a theme
Ehrnhoefer, D. E., Butland, S. L., Pouladi, M. A., & Hayden, M. R. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002451 · Cited by 100
Therapeutic interventions for disease progression in Huntington's disease
Mestre, T., Ferreira, J. J., Coelho, M. M., Rosa, M. M., & Sampaio, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006455.pub2 · Cited by 100
Huntington's Disease
MacDonald, M. E., Ginés, S., Gusella, J. F., & Wheeler, V. C. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:7 · Cited by 104
The relationship between CAG repeat length and clinical progression in Huntington's disease
Ravina, B. M., Romer, M., Constantinescu, R., Biglan, K., Brocht, A. F. D., Kieburtz, K. D., Shoulson, I., & McDermott, M. (2008) · Movement Disorders · doi:10.1002/mds.21988 · Cited by 99
Therapy development in Huntington disease: From current strategies to emerging opportunities
Dickey, A. S., & Spada, A. R. L. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38494 · Cited by 103
Clinical correlates of mitochondrial function in Huntington's disease muscle
Turner, C., Cooper, J. M., & Schapira, A. H. V. (2007) · Movement Disorders · doi:10.1002/mds.21540 · Cited by 97
A futility study of minocycline in Huntington's disease
Cudkowicz, M., & The Huntington Study Group DOMINO Investigators (2010) · Movement Disorders · doi:10.1002/mds.23236 · Cited by 97
Modelling brain diseases in mice: the challenges of design and analysis
Watase, K., & Zoghbi, H. Y. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1045 · Cited by 94
Cellular Consequences of Coenzyme Q10 Deficiency in Neurodegeneration of the Retina and Brain
Manzar, H., Abdulhussein, D., Yap, T. E., & Cordeiro, M. F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239299 · Cited by 97
The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease
Haas, R. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.008 · Cited by 92
Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects
The Huntington Study Group Pre2CARE Investigators (2010) · Movement Disorders · doi:10.1002/mds.22408 · Cited by 91
The relationship between uric acid levels and Huntington's disease progression
Auinger, P., Kieburtz, K. D., & McDermott, M. (2010) · Movement Disorders · doi:10.1002/mds.22907 · Cited by 90
Pharmacologic approaches to the treatment of Huntington's disease
Venuto, C. S., McGarry, A. J., Ma, Q., & Kieburtz, K. D. (2011) · Movement Disorders · doi:10.1002/mds.23953 · Cited by 93
Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice
Schilling, G., Savonenko, A. V., Coonfield, M. L., Morton, J. L., Vorovich, E. B., Gale, A., Neslon, C., Chan, N., Eaton, M., Fromholt, D., et al. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.01.003 · Cited by 85
Alternative designs for clinical trials in rare diseases
Abrahamyan, L., Feldman, B. M., TOMLINSON, G. A., Faughnan, M. E., Johnson, S. R., Diamond, I. R., & Gupta, S. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31533 · Cited by 87
A Water Soluble CoQ10 Formulation Improves Intracellular Distribution and Promotes Mitochondrial Respiration in Cultured Cells
Bergamini, C., Moruzzi, N., Sblendido, A., Lenaz, G., & Fato, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033712 · Cited by 84
Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases
Testai, L., Martelli, A., Flori, L., Cicero, A. F. G., & Colletti, A. (2021) · Nutrients · doi:10.3390/nu13051697 · Cited by 86
Bioequivalence of coenzyme Q10 from over-the-counter supplements
Miles, M. V., Horn, P. S., Miles, L., Tang, P., Steele, P. E., & deGrauw, T. J. (2002) · Nutrition Research · doi:10.1016/s0271-5317(02)00402-5 · Cited by 81
The spinocerebellar ataxias: Order emerges from chaos
Margolis, R. L. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0072-8 · Cited by 81
Animal models of Huntington's disease for translation to the clinic: Best practices
Menalled, L., & Brunner, D. (2014) · Movement Disorders · doi:10.1002/mds.26006 · Cited by 82
Interrater agreement in the assessment of motor manifestations of Huntington's disease
Hogarth, P., Kayson, E., Kieburtz, K. D., Marder, K. S., Oakes, D., Rosas, H. D., Shoulson, I., Wexler, N. S., Young, A. B., Zhao, H., et al. (2004) · Movement Disorders · doi:10.1002/mds.20332 · Cited by 78
Self-citation
Treatment of Parkinson???s Disease
Wu, S., & Frucht, S. J. (2005) · CNS Drugs · doi:10.2165/00023210-200519090-00001 · Cited by 78
Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease.
Ryu, J. K., Choi, H. B., & McLarnon, J. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.05.043 · Cited by 83
Coenzyme Q treatment of neurodegenerative diseases of aging
Galpern, W. R., & Cudkowicz, M. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.01.004 · Cited by 78
Coenzyme Q10 a mitochondrial restorer for various brain disorders
Pradhan, N., Singh, C., & Singh, A. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02161-8 · Cited by 79
Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults
Miles, M. V., Horn, P. S., Morrison, J. A., Tang, P., deGrauw, T. J., & Pesce, A. J. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00137-2 · Cited by 77
Therapeutic role of coenzyme Q10 in Parkinson's disease
Shults, C. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.02.002 · Cited by 81
A Randomized, Double-Blind, Placebo-Controlled Study of Oral Coenzyme Q10 to Relieve Self-Reported Treatment-Related Fatigue in Newly Diagnosed Patients with Breast Cancer
Lesser, G. J., Case, D., Stark, N. N., Williford, S., Giguere, J. K., Garino, L. A., Naughton, M. J., Vitolins, M. Z., Lively, M. O., & Shaw, E. G. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.03.003 · Cited by 77
Microencapsulation of ubiquinone-10 in carbohydrate matrices for improved stability
Bule, M. V., Singhal, R. S., & Kennedy, J. F. (2010) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2010.07.012 · Cited by 77
Translating therapies for Huntington’s disease from genetic animal models to clinical trials
Hersch, S. M., & Ferrante, R. J. (2004) · NeuroRx · doi:10.1602/neurorx.1.3.298 · Cited by 75

Authors: The Huntington Study Group
Corresponding author: The Huntington Study Group
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2001-08-14
Volume: 57
Issue: 3
Pages: 397-404
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.57.3.397
OpenAlex: W4245847463
Cited by: 312
References: 19
Citations by year: 2026: 2 · 2025: 8 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 10 · 2020: 8 · 2019: 9 · 2018: 12 · 2017: 11 · 2016: 11 · 2015: 3 · 2014: 9 · 2013: 5 · 2012: 16
FWCI: 7.24
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Neurological Disorders and Stroke (NS R01-35284, R01NS035284)
National Center for Research Resources (RR-00044, RR 01066, RR 07122, M01RR001066, M01RR000044, RR00042, RR 00645, M01RR000042, M01RR000645)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords: Huntington's disease, coenzyme Q10, remacemide, functional decline, total functional capacity, disease-modifying therapy, early-stage Huntington's disease, adverse events, nausea and vomiting
MeSH terms: Acetamides, Adult, Coenzymes, Double-Blind Method, Female, Humans, Huntington Disease, Male, Middle Aged, Prognosis, Time Factors, Ubiquinone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks